Block-and-Replace or Titrate: Two Ways to Run the Same Drug Trial
A newly diagnosed Graves' patient is starting antithyroid drug therapy, and two clinicians who agree on the drug disagree on the strategy — a fixed higher dose kept stable with added levothyroxine, or a lower dose continuously adjusted down as her labs improve.
Beatriz A., a 34-year-old restaurant manager, was diagnosed with Graves' disease three weeks ago after months of unexplained irritability she and her family had chalked up to the stress of opening a second location. Her free T4 at diagnosis was more than three times the upper limit of normal, with a TSH too low to detect and a moderately elevated TSH-receptor antibody titer — florid enough that whichever strategy she starts on, she will be on it for the eighteen months a full antithyroid-drug course runs. She also works long, irregular restaurant hours, and has said plainly that getting to frequent appointments is the part she cannot promise. She was started on methimazole 20mg daily and returns today for her first follow-up, her symptoms already improving but her labs not yet rechecked. Her endocrinologist and the covering physician seeing her today disagree, mildly but genuinely, about how to structure the next eighteen months of her treatment.
The two approaches aren't different drugs, they're different philosophies for running the same one. Titration keeps adjusting the methimazole dose downward as her own thyroid function recovers, aiming for the lowest dose that keeps her stable. Block-and-replace holds methimazole at a fixed, deliberately higher dose that fully suppresses her own thyroid output, and adds levothyroxine back in to prevent the hypothyroidism that dose would otherwise cause — a strategy built around the idea that fewer dose changes means fewer chances for her labs to swing out of range between visits. Abraham and colleagues' Cochrane review comparing the two regimens found no meaningful difference in her most important outcome, long-term remission rate, but did find block-and-replace carries a higher rate of drug-related side effects — unsurprising, since the strategy commits her to a higher cumulative methimazole dose across the full treatment course by design, not by accident.
At the first follow-up, choosing a strategy for the next eighteen months
I'd titrate. The comparative evidence — Abraham's Cochrane review, pooling the available trials — found no remission-rate advantage to block-and-replace, and a genuinely higher rate of drug-related side effects, which makes sense given it exposes her to a larger cumulative methimazole dose across the whole course by design. If the outcome that matters most isn't different, I don't see a reason to accept more side-effect risk to get there.
I hear the side-effect data, but I'd weigh her actual life against it. She's told us plainly her schedule makes frequent visits hard, and titration only works well with the lab-monitoring cadence it assumes — block-and-replace's whole appeal is that a stable, fixed dose is more forgiving of a missed or delayed follow-up than a strategy that depends on catching and correcting drift in real time.
You're citing the side-effect data as though it settles this for every patient equally, but that comparison assumes both strategies get monitored on the same schedule — for a patient who may not reliably make every visit, an unmonitored titration regimen drifting toward under- or over-treatment is its own real risk that the trial data comparing well-monitored patients in both arms doesn't capture.
I'd start with titration and revisit block-and-replace specifically if her visit pattern turns out to actually be unreliable, rather than deciding that in advance based on a schedule concern she's raised but hasn't yet demonstrated. The side-effect data is real and shouldn't be traded away preemptively for a monitoring problem that might not materialize. If she misses two consecutive follow-ups, that's the concrete signal to switch strategies — not a hypothetical worth committing to more medication exposure today.
Agreed: start with titration, with a concrete trigger — two consecutive missed follow-ups — for switching to block-and-replace if her visit pattern turns out to be unreliable.
Not agreed: whether that trigger is the right threshold. The primary care physician would switch after a single missed visit, seeing no reason to let her labs drift twice before adjusting the strategy; the endocrinologist preferred giving titration a genuine chance to prove workable before abandoning the lower-side-effect option on the strength of one schedule conflict.